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Abstract
Background. Portuguese type familial amyloid poly-
neuropathy (FAP) is a neuropathic amyloidosis caused
by a mutant transthyretin (TTR). Varying degrees
of renal involvement have been reported. Our aim was
to assess the value of microalbuminuria (MA) for
predicting clinical neurological disease and overt
nephropathy in TTR-related amyloidosis.
Methods. All subjects had the TTR Val30Met muta-
tion, and were recruited between 1993 and 1999. We
have prospectively evaluated 22 asymptomatic gene
carriers (7 male, 15 female; mean age 41.6"9.6 years)
and 32 patients with neuropathy (14 male, 18 female;
36.8"8.8 years, on average, 33.0"9.3 years at the
onset of neuropathy). We measured urinary albumin
excretion every year, if asymptomatic, or every
6 months if already affected. Kidney biopsies were
performed in patients with normal urinary albumin
excretion, MA, and overt nephropathy, respectively.
Results. In asymptomatic carriers, persistent MA was
detected in eight (36%) subjects. The presence of MA
in asymptomatic gene carriers, compared with those
having normal urinary albumin excretion, conferred
a 4.8-fold risk of developing neuropathy, usually
within the subsequent 3 years. Once neurological
signs appeared, nephropathy, manifested as MA, pro-
gressed to overt nephropathy in one-half of subjects. In
patients with neuropathy, 24 (75%) had MA during
follow-up: evolution towards clinical renal disease
occurred in 14 (58%) and renal failure occurred in
ﬁve (21%), always after a course of MA. Proteinuria or
renal failure without prior persistent MA were never
observed in the present patient cohort. Histopatho-
logical evaluation did not reveal glomerular lesions
other than amyloid deposits to explain abnormal
urinary albumin excretion. The amount of mesangial
and vascular-pole amyloid deposits was correlated
with the degree of albuminuria.
Conclusions. Microalbuminuria represents the ﬁrst stage
of clinical TTR amyloid nephropathy and is pre-
monitory of neuropathy. Its presence identiﬁes a
subgroup of patients who are more prone to develop
overt nephropathy. Screening of MA may be impor-
tant to assess disease onset and to recommend liver
transplantation in individuals at risk.
Keywords: amyloidosis; glomerular; kidney; micro-
albuminuria; proteinuria; transthyretin
Introduction
Familial amyloidoses are genetic disorders often
caused by mutations in the transthyretin (TTR) gene
[1]. The majority of TTR mutations are associated
with amyloid neuropathy, cardiomyopathy, or nephro-
pathy. To date more than 60 TTR amyloidogenic
mutations have been found, but TTR Val30Met
(familial amyloid polyneuropathy type I, FAP) is by
far the most frequent [2]. The TTR Val30Met mutation
has a worldwide distribution, and Portugal is the main
geographic focus of this disease. Hereditary forms of
amyloidosis involving the kidney were also related to
mutations of apolipoprotein A-I and A-II [3,4],
ﬁbrinogen [5], lysozyme [6], and gelsolin [7] genes.
Familial Mediterranean fever (FMF), and Muckle–
Wells syndrome are the two hereditary varieties of AA
amyloidosis, and in both, proteinuria and renal failure
may complicate the clinical course [8,9]. All are
inherited in an autosomal dominant mode, except for
FMF, which is transmitted as an autosomal recessive
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trait. An autosomal dominant periodic fever occasion-
ally associated with AA amyloidosis was also reported
in families of European origin, revealing missense
mutations in the gene encoding the tumour necrosis
factor receptor [10,11].
The pre-clinical stage of amyloid-associated nephro-
pathy can be detected only by histological examina-
tion. The number of patients at this stage is unknown,
as repeated urinalysis showed no abnormalities in
biopsy-proven renal amyloidosis [8,12].
Early detection of organ dysfunction caused by
amyloid deposits has particular emphasis in TTR-
related amyloidosis (ATTR), as it may determine pro-
gnosis and allocation in liver transplant programmes,
which is the speciﬁc treatment for this disease [13].
FAP usually manifests as a sensorimotor neuro-
pathy with autonomic dysfunction. Life-span of this
disease, before liver transplantation was accepted as a
treatment, was on average 11 years. Renal features of
amyloid glomerular involvement can affect one-third
of ATTR Val30Met patients [14]. Nephropathy occurs
commonly with progression of the neurological dis-
ease, but in some instances may be present from the
onset [15].
The aim of this study was to assess the value of
microalbuminuria as a predictor of neuropathy and
nephropathy in ATTR amyloidosis. In addition, we
explored whether different levels of urinary albumin
excretion may reﬂect differences in glomerular amy-
loid deposition, establishing a correlation of micro-
albuminuria with pathological ﬁndings. We excluded
confounding factors in the interpretation of micro-
albuminuria, such as high blood pressure, diabetes, and
obesity.
Subjects and methods
Patients
Asymptomatic gene carriers and patients who had already
developed neuropathy, all with TTR Val30Met mutation,
were recruited from the registries of Centro de Estudos de
Paramiloidose (CEP), during the period 19931999, and
were prospectively followed.
As mean age-at-onset of neuropathy is 31.9 (1778) years,
in males, and 35.6 (20–74) years, in females [14], we asked for
the participation of asymptomatic subjects older than 25
years. All subjects had a preliminary contact in which we
explained our objectives, and consented to come regularly for
a medical nephrological evaluation.
Exclusion criteria were clinical or laboratory evidence of
other disease (including hyperglycaemia, glycosuria, and
obesity), and patients receiving angiotensin-converting-
enzyme inhibitor and other medication affecting blood
pressure. We registered symptoms, age at onset, neurological
examination, and electrocardiogram disturbances. Patients
were then asked to collect 24-h urine samples and to avoid
exercise prior to the test. Urine collection was repeated if
bacteriuria or pyuria were present. Twenty-nine asymptomatic
and 38 patients with neuropathy participated in this study.
Subjects were re-examined every year, if asymptomatic,
or every 6 months if with overt disease. Blood-pressure
measurement (in the morning, after rest, in the seated position,
by mercury sphygmomanometer), 24-h urine collection, and
blood sample analysis were repeated at each visit. Patients who
developed any of the exclusion criteria mentioned above, or
had a serum creatinineP1.3 mgudl, or serum ureaP50 mgudl,
or proteinuria in the ﬁrst evaluation, were excluded from
follow-up. Kidney ultrasound was performed whenever an
abnormal urine analysis was detected, excluding cortical
scarring or obstructive uropathy. Our follow-up ended in
December 2000 or when the patient underwent orthotopic
liver transplantation. If this was the case, kidney biopsies were
performed as part of the pre-operative evaluation, after
obtaining written informed consent.
Assays
DNA analysis by PCR ampliﬁcation was used to detect the
TTR Val30Met mutation in all subjects. Urinary albumin
excretion (UAE) was measured by immunoturbidimetric
method (Roche Diagnostics), with a limit of detection of
0.6 mgudlandaninterassayvariationof4.3%.Microalbuminuria
(MA) was deﬁned as UAE P20 mgumin and O200 mgumin
in two measurements with a week’s interval. Overt
nephropathy was deﬁned as UAE )200 mgumin.
Serum and urinary creatinine concentrations were mea-
sured by standard colorimetric methods. Creatinine clearance
was used as an index of glomerular ﬁltration rate. We con-
sidered there to be renal failure when the creatinine clearance
was -80 mluminu1.73 m2.
Each renal biopsy was ﬁxed in formol for Congo-red
staining, and frozen for indirect immunoperoxidase tech-
nique with anti-TTR monoclonal antibody [15,16]. The
presence and amount of amyloid, graded on a scale from 
(absent) toqqq (more than 50% of the structure involved)
was analysed in the glomerular structures by light
microscopy, as described previously [15].
Statistical analysis
Comparisons between groups with nephropathy or ESRD
and without nephropathy were performed with the chi-
square statistic, in the case of categorical variables, and the
Student t-test in the case of continuous variables; relative risk
(RR) to develop neuropathy was expressed with 95% con-
ﬁdence interval (CI). Descriptive statistics were given as
average"SD;P-0.05 was regarded as statistically signiﬁcant.
Results
In the ﬁrst evaluation, we studied 29 asymptomatic
gene carriers (9 malesu20 females), and 38 patients
with neuropathy (16 malesu22 females). Overt nephro-
pathy was diagnosed in one asymptomatic subject and
three patients. Nine subjects showed exclusion criteria
for follow-up. Our analysis was thus based on 22
asymptomatic carriers (7 malesu15 females), and 32
patients (14 malesu18 females).
Microalbuminuria: prevalence and evolution to
overt nephropathy
Asymptomatic carriers. Table 1 details clinical
characteristics at ﬁrst examination, and Figure 1
resumes the evolution during follow-up. Neuropathy
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developed, on average, 2.3"2.2 years after detection
of microalbuminuria. One subject developed micro-
albuminuria (34.2 mgumin) on the third and last year
of follow-up, and was still asymptomatic.
Development of neuropathy in asymptomatic gene
carriers with microalbuminuria was signiﬁcantly more
frequent than in those with normal urinary albumin
excretion (7u8 vs 6u14; Ps0.04). The relative risk for
asymptomatic gene carriers with microalbuminuria
developing neuropathy was 4.8 (95% CI, 0.732.9),
meaning that among asymptomatic carriers, there was
a 4.8-fold risk of becoming neuropathic, compared to
subjects with normal urinary albumin excretion.
When microalbuminuria preceded the onset of neuro-
logical symptoms, evolution to overt renal disease
occurred in three of seven cases, and in all of them
during the ﬁrst year of neurological symptoms. None
of the cases starting neurological symptoms with normal
urinary albumin excretion evolved to clinical nephro-
pathy, after a period of 26 years of observation
from the onset of neuropathy.
No sex differences were registered respecting
presence or development of microalbuminuria.
Patients with neuropathy. Table 1 shows clinical
characteristics of patients when the study began. In
13 patients (4 malesu9 females) microalbuminuria
was detected at the beginning of the study, and in 11
(5 malesu6 females) microalbuminuria developed
subsequently, on average, after 3.2"1.7 years of
follow-up.
Figure 2 summarizes the evolution of renal disease in
neuropathic patients. Evolution to overt nephropathy
occurred in 13 (3 malesu9 females) of the 24 patients in
whom microalbuminuria was detected; conversely,
renal disease was absent in the 10 subjects (5 malesu5
females) maintaining normal urinary albumin excretion
during the follow-up (Ps0.006). First urinary albumin
excretion )30 mgumin had a signiﬁcantly higher rate
of progression to overt nephropathy, compared with
urinary albumin excretion between 20 and 30 mgumin
(9u10 vs 0u3; P-0.001), within the same time of follow-
up (respectively 3.7"2.2 vs 3.3"1.2 years; PsNS). The
urinary albumin excretion was initially -30 mgumin in
the two patients who evolved having UAE-20 mgumin
at the end of follow-up.
Overall evolution to overt nephropathy and renal failure.
In our series, overt nephropathy was found in 16u32
subjects with a previous course of persistent micro-
albuminuria, but was absent in the 24 subjects main-
taining normal urinary albumin excretion (P-0.0001).
The mean time between detection of microalbuminuria
and overt nephropathy was 2.0"1.7 years; in these
cases, the ﬁrst determination of albumin excretion was
97.8"74.6 mgumin.
Renal failure was found in ﬁve of 16 subjects, and
occurred 15 years after detection of microalbumin-
uria; in four patients, renal failure developed after overt
nephropathy and in one it occurred during the course of
microalbuminuria, but was never associated with
normal urinary albumin excretion.
Renal disease, evolution of neuropathy and age. Micro-
albuminuria appeared, on average, after 4.6"3.8
years of neuropathy (4.1"3.5 years for women, and
5.8"4.5 years for men; P-104); it was most likely to
appear during the ﬁrst years of neuropathy (Figure 3),
78% in the ﬁrst 7 years. Evolution to clinical nephro-
pathy occurred after a mean duration of neuropathy
of 6.8"4.7 years.
Table 1. Clinical characteristics of asymptomatic carriers and
patients with neuropathy at ﬁrst urine collection
Asymptomatic Neuropathy
n subjects (MuF) 22 (7u15) 32 (14u18)
Age (years) 41.6"9.6 36.8"8.8
No microalbuminuria
n subjects 19 19
UAE (mgumin) 8.8"4.0 8.0"4.3
sBP (mmHg) 130.0"22.9 112.1"14.7
dBP (mmHg) 83.1"10.1 72.9"9.9
Microalbuminuria
n subjects 3 13
UAE (mgumin) 122.5"56.6 83.9"68.6
sBP (mmHg) 124.0"19.7 112.0"13.1
dBP (mmHg) 73.3"5.7 73.8"9.3
Follow-up (years) 6.1"1.3 3.7"1.9
n, number; M, males; F, females; sBP, systolic blood pressure; dBP,
diastolic blood pressure; UAE, urinary albumin excretion.
Fig. 1. Asymptomatic gene carriers: evolution to neuropathy and nephropathy during a mean follow-up of 6.1"1.3 years. Numbers of
subjects with each clinical condition.
534 L. Lobato et al.
 at H
ospitais da U
niversidade de C
oim
bra on July 6, 2011
ndt.oxfordjournals.org
D
ow
nloaded from
 
The age at onset of neuropathy was not different in
subjects with UAE-20 and withP20 mgumin (37.8"
11.4 vs 35.6"11.4 years; PsNS), but when these
values were )100 mgumin the onset was signiﬁcantly
later (48.0"14.9 vs 35.6"10.5 years; Ps0.01).
Microalbuminuria and blood pressure. We analysed
systolic and diastolic blood pressure in asymptomatic
carriers and patients with neuropathy, at the begin-
ning of the study and at the end (Tables 1 and 2).
Blood pressure lowered when neuropathy was estab-
lished, even in the presence of microalbuminuria.
Thereafter, renal failure, not just proteinuria, was
associated with an increase in systolic and diastolic
blood pressure.
Serum albumin, lipids, and uric acid. Establishment of
neuropathy sloped down serum albumin, total serum
cholesterol, serum triglycerides, and uric acid. Patients
with microalbuminuria had a lower serum albumin
level and higher uric acid level, but the same lipid
concentration compared to those with normal urinary
albumin excretion. Progression to overt nephropathy
was associated with a tendency toward elevation in
serum triglycerides and uric acid, and a decrease in
serum albumin; total cholesterol raised only in the
presence of renal failure. Analytic data are shown in
Table 2.
Renal biopsies. Renal biopsy was performed in 14
patients, all undergoing liver transplantation: three
with normal albumin excretion, seven with
Fig. 2. Patients with neuropathy: albuminuria and evolution of nephropathy during a mean follow-up of 3.7"1.9 years. Numbers of patients
with each clinical condition.
Fig. 3. Distribution of microalbuminuria and nephropathy during
evolution of neuropathy in years; negative values represent years
before onset of neuropathy. MA, microalbuminuria; Neph, protein-
uria or renal failure.
Table 2. Clinical data of 54 subjects at the end of follow-up
No neuropathy Neuropathy
No microalbuminuria Microalbuminuria Proteinuria Proteinuria and renal failure
%, n MuF 16.6, 4u5 26, 7u7 27.8, 5u10 18.5, 4u6 11.1, 2u4
Systolic BP (mmHg) 133.1"12.6 118.1"15.1 114.4"30.1 102.3"26.3 144.7"23.7
Diastolic BP (mmHg) 86.9"7.5 76.0"7.3 72.6"14.1 66.9"18.0 87.9"14.5
Creat. clear. (mluminu17.3 m2) 122.6"13.9 97.4"20.0 98.4"19.2 104.1"20.0 28.8"18.5
Plasma albumin (gudl) 4.79"0.3 4.5"0.4 3.9"0.5 3.8"0.6 3.6"0.6
Serum cholesterol (mgudl) 219.6"35.0 167.0"48.1 171.4"53.3 170.3"41.8 230.1"79.8
Serum triglycerides (mgudl) 125.4"38.9 84.4"30.0 88.1"32.0 127.5"75.5 143.3"69.3
Serum uric acid (mgudl) 4.7"1.1 4.4"1.0 5.3"1.8 5.9"2.3 6.9"2.0
n, number; M, males; F, females; BP, blood pressure; Creat. clear., creatinine clearance.
535Microalbuminuria in hereditary transthyretin amyloidosis
 at H
ospitais da U
niversidade de C
oim
bra on July 6, 2011
ndt.oxfordjournals.org
D
ow
nloaded from
 
microalbuminuria, and four with overt nephropathy
after a course of microalbuminuria. Table 3 details the
presence and amount of glomerular amyloid deposits.
Normal urinary albumin excretion corresponded
to absent or very clear involvement. The presence
of microalbuminuria corresponded to mesangial or
vascular pole deposition in all cases. The level of
albuminuria generally correlated with the extension
of mesangial deposits as described previously [15].
Arterioles of the juxtaglomerular apparatus (vascular
pole) were not involved or had only mild deposits
when microalbuminuria was -90 mgumin.
In one patient with overt nephropathy, who entered
the study as an asymptomatic carrier with micro-
albuminuria, we observed a less extensive mesangial
deposition when compared with other patients with
microalbuminuria: he had amyloid vascular deposits in
the arterioles and interlobular arteries, and deposition
in subendothelial spaces.
We never found glomerular or vascular lesions other
than amyloid deposits.
Discussion
The most frequent presentation of amyloid nephro-
pathy is proteinuria, with variable degrees of renal
insufﬁciency [17]. Although the pathogenic mechanism
in diabetes and amyloid nephropathy are different,
some common structural defects [18] could have simi-
lar consequences. Increased protein excretion, mani-
fested as microalbuminuria, is the earliest clinical
ﬁnding of diabetic nephropathy [19]. These observa-
tions prompted investigation of urinary albumin
excretion in ATTR Val30Met amyloidosis.
Microalbuminuria precedes neuropathy and overt
renal disease
In the current study, the diagnosis of microalbumin-
uria prior to the ﬁrst complaints of FAP, was made
in 32 percent of carriers. The presence of micro-
albuminuria in asymptomatic gene carriers, compared
with those having normal urinary albumin excretion,
gave a 4.8-fold risk of developing neuropathy, usually
within the next 3 years. The follow-up of individuals
at risk showed that once neurological signs have
appeared, nephropathy (manifested as early micro-
albuminuria) progressed to overt renal disease in
almost one-half of the cases.
The analysis of subjects that already had neuropathy
when microalbuminuria was detected showed also
that one-half developed overt nephropathy later. Pro-
gression to clinical nephropathy was associated with
urinary albumin excretion levels )30 mgumin, which
probably has a higher discriminatory value for pre-
dicting outcome than the level of 20 mgumin. Levels
of urinary albumin excretion )100 mgumin at presen-
tation occurred in patients with later onset of neuro-
pathy, so special attention must be devoted to follow-up
of older subjects.
Subjects maintaining normal urinary albumin excre-
tion during the follow-up did not evolve to clinical
nephropathy.
Time between detection of microalbuminuria and
overt renal disease was 2 years. First urinary albumin
excretion had a level near 100 mgumin on those who
progressed, suggesting that a higher interval of pro-
gression from sub-clinical to overt nephropathy could
have been obtained if our starting point had been
earlier.
We think it is advisable that an asymptomatic
gene carrier with repeated urinary albumin excretion
)30 mgumin should be put on a liver transplant list.
Renal failure occurring after a course
of microalbuminuria
Renal failure on TTR Val30Met amyloidosis develo-
ped in 18.8% of the subjects with a previous course of
microalbuminuria and in one-third of those with overt
nephropathy, but did not emerge with normal urinary
Table 3. Clinical data and quantiﬁcation of amyloid in the glomeruli after renal biopsy (ns14)
Urine ﬁndingsa
Albuminuria mgumin
or Pt guday
Duration of
neuropathy
in yearsa
Years of
follow-upa
Number of
glomeruli
Glomerular
basement
membrane
Mesangium Vascular
pole
5.3 mgumin 1 6 18   
7 mgumin 4 4 12  uq uq
19.9 mgumin 2 1 22  q 
27.3 mgumin 3 5 25  qq uq
31.6 mgumin 3 6 48  q uq
46.2 mgumin 4 3 7  uq uq
72.0 mgumin 5 1 15  qq 
91.9 mgumin 7 2 31  qq qq
148.8 mgumin 5 2 14  qq q
168.9 mgumin 2 7 20  qq q
1 guday 0.5 7 28 uq  q
1.5 guday 5 3 28  qqq qq
2 guday 1 7 23 q q q
4 guday 5 3 24  qqq qq
aPrior to biopsy; Pt, proteinuria; , absent; uq, very mild; q, -25%; qq, 25–50%; qqq, )50%.
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albumin excretion. Renal failure always occurred after
neuropathy began.
Microalbuminuria was not associated with an increase
in blood pressure or dyslipidaemia
FAP patients with microalbuminuria did not show an
increase in blood pressure or serum lipids; only overt
nephropathy later changed these parameters. We did
not register either the highly signiﬁcant effect of
hypertension on microalbuminuria of FAP, as seen
in diabetes mellitus [20], or the association to hyper-
lipidaemia as described in essential hypertension [21].
Other risk factors for early nephropathy in FAP
should be investigated. Modiﬁcations of the trans-
thyretin catabolism or intracellular environment, inter-
actions of the amyloid precursor with mesangium or
basement membrane components may represent the
clues for renal disease.
The extent of glomerular amyloid deposits was related
to microalbuminuria
The amount of mesangial and vascular pole amyloid
deposits showed correlation with the level of albumin
in the urine. The arterioles of the juxtaglomerular
apparatus were more extensively involved when micro-
albuminuria was )90 mgumin. Therefore, although
hypertension was not related with microalbuminuria,
vascular pole amyloidosis may have a functional impact
on glomerular capillary pressure and a prognostic
value for the evolution of nephropathy.
Autonomic dysfunction did not explain micro-
albuminuria. In other diseases with autonomic dys-
function such as familial dysautonomia (Riley–Day
syndrome), lower creatinine clearances were related to
disturbed renal haemodynamics, not to speciﬁc glo-
merular disease [22]. A study of renal disease in
familial dysautonomia [23] identiﬁed excess glomerulo-
sclerosis as a frequent ﬁnding on autopsy or biopsy
cases; renal disease was attributed to ischaemia due to
hypotension and subsequent sclerosis of glomeruli. Our
biopsy ﬁndings in patients with microalbuminuria
did not reveal sclerosis of glomeruli, suggesting that
albumin excretion did not correlate with ischaemia.
Variation on renal haemodynamics, however, can
explain how two patients with microalbuminuria
reached the end of follow-up with normal albuminuria,
although both had had urinary albumin excretion levels
-30 mgumin at ﬁrst determination. This fact reinforces
the discrimination value of albuminuria)30 mgumin in
predicting outcome.
Autonomic symptoms can become manifest after the
onset of FAP, and dysautonomia becomes more severe
as the disease progresses. However, microalbuminuria
and subsequent nephropathy occur mostly during the
ﬁrst 7 years of FAP, with new cases sparsely thereafter.
In summary, the ﬁndings of the current study are
consistent with the conclusion that microalbuminuria
represents a ﬁrst stage of clinical amyloid nephropathy
and could be premonitory of neuropathy. Elevated
levels of urinary albumin appeared during the ﬁrst
years of FAP, disclosing a subpopulation with higher
risk of developing renal disease.
Liver transplantation currently appears to be the
only treatment for FAP, and should be performed
during the early phases of disease. The organ damage
caused by amyloid seems to be irreversible, and the
mortality and morbidity for patients transplanted in
later stages are unacceptably high [24]. Screening for
microalbuminuria may be important for therapeutic
decisions in individuals at risk, identifying who will
beneﬁt from early liver transplantation.
We recommend the systematic and regular measure-
ment of urinary albumin excretion in asymptomatic
gene carriers and patients, instead of renal biopsy, as a
non-invasive method for estimating the progression of
glomerular transthyretin amyloidosis.
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